Item 7.01 Regulation FD Disclosure.
In fourth quarter 2019,
Baxter remains confident in the fundamentals of the Novum IQ platform. To date,
Baxter plans to provide additional details regarding the anticipated timing and
nature of these updated submissions on its upcoming earnings call for third
quarter 2020, currently scheduled for
This Form 8-K may contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, including with respect to
statements regarding the anticipated timing of the Company's resubmission of the
application referenced above to FDA and its view as to the design, safety and
effectiveness of the Novum IQ infusion platform. Use of the words "may," "will,"
"would," "could," "should," "believes," "estimates," "projects," "potential,"
"expects," "plans," "seeks," "intends," "evaluates," "pursues," "anticipates,"
"continues," "designs," "impacts," "affects," "forecasts," "target," "outlook,"
"initiative," "objective," "designed," "priorities," "goal," or the negative of
those words or other similar expressions is intended to identify forward-looking
statements that represent our current judgment about possible future events. The
statements are based on assumptions about many important factors, including the
following, which could cause actual results to differ materially from those in
the forward-looking statements: future discussions with and actions of FDA and
other risks identified in Baxter's most recent filings on Forms 10-K and 10-Q
and other
--------------------------------------------------------------------------------
© Edgar Online, source